PRT versus IMRT toxicity in Medicare beneficiaries with prostate cancer
There is no difference between proton radiotherapy (PRT) and intensity-modulated radiotherapy (IMRT) when comparing the toxicity among Medicare beneficiary patients with prostate cancer at 12 months post-treatment according ...
Cancer
Dec 17, 2012 |
not rated yet |
0
|
Changes in penile length after radical prostatectomy studied
(HealthDay)—Although penile shortening of about 1 cm can occur at three months after a radical prostatectomy (RP) for the treatment of localized prostate cancer, recovery of penile length begins after 24 ...
Diseases, Conditions, Syndromes
Dec 16, 2012 |
not rated yet |
0
Adoptive cell transfer: New technique could make cell-based immune therapies for cancer safer, more effective
A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development ...
Cancer
Dec 16, 2012 |
5 / 5 (2) |
0
|
Despite hype, costly prostate cancer treatment offers little relief from side effects
Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a standard radiation ...
Cancer
Dec 13, 2012 |
not rated yet |
0
|
40 percent of cancer patients receive opioids at end of life
(HealthDay)—For patients with one of five common cancers, 43.6 percent receive at least one prescription of opioids in the last three months of life, according to a study published in the Dec. 10 issue ...
Medications
Dec 13, 2012 |
not rated yet |
0
Researchers find new culprit in castration-resistant prostate cancer
Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They ...
Cancer
Dec 13, 2012 |
not rated yet |
0
|
Abiraterone benefits chemo-naive with advanced prostate CA
(HealthDay)—For chemotherapy-naive patients with metastatic castration-resistant prostate cancer, abiraterone acetate correlates with improved radiographic progression-free survival, according to a study ...
Cancer
Dec 12, 2012 |
not rated yet |
0
FDA OKs expanded use of prostate cancer drug
(HealthDay)—The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food ...
Medications
Dec 10, 2012 |
not rated yet |
0
Prostate cancer now detectable by imaging-guided biopsy
Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.
Cancer
Dec 10, 2012 |
not rated yet |
0
Longer life expectancy, aging population necessitate new strategies for prostate cancer care
The population of the United States is getting older, due not only to aging boomers but also to a four-year increase in life expectancy from 1990 to 2010. An aging population means increased diagnosis of prostate cancer. ...
Cancer
Dec 04, 2012 |
not rated yet |
0
Clinical trial targets advanced prostate cancer
Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.
Cancer
Dec 03, 2012 |
5 / 5 (1) |
0
Clinical trial hits new target in war on breast cancer
Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer ...
Cancer
Dec 03, 2012 |
5 / 5 (2) |
0
|
Cabozantinib active in castration-resistant prostate cancer
(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. ...
Cancer
Dec 03, 2012 |
not rated yet |
0
Researchers develop novel treatment for prostate cancer
(Medical Xpress)—The work of a team of Wake Forest researchers developing a novel drug for prostate cancer treatment is featured on the cover of the Nov. 26 issue of the Journal of Medicinal Chemistry.
Cancer
Nov 29, 2012 |
5 / 5 (2) |
0
COUP-TFII sparks prostate cancer progression
Prostate cancer presents a dilemma for patients and the physicians who treat them. Which cancers are essentially indolent and present no risk and which are life threatening? Which can be watched and which need aggressive ...
Cancer
Nov 28, 2012 |
not rated yet |
0
|
